Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Crucell N.V. (CRXL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (93)	1/27/2003 4:05:12 AM
From: nigel bates	Read Replies (1) \| Respond to of 560

LEIDEN, The Netherlands, Jan. 27, 2003 (PRIMEZONE) -- Crucell N.V. (NasdaqNM:CRXL - News) and Aventis Pasteur S.A. (NYSE:AVE - News) today announced that they have signed a commercial license agreement for manufacturing technology related to viral vaccines. The agreement allows Aventis Pasteur to use Crucell's cell-based vaccine manufacturing technology to develop and commercialize next generation vaccines. Crucell will receive upfront payments, milestone payments and royalties on future product sales. Further financial details of the agreement were not disclosed. ``Aventis Pasteur is one of the world's largest vaccine producers,'' said Crucell's CEO Dinko Valerio. ``Being able to collaborate with such an established player in this field provides an important further endorsement of our manufacturing technology in the vaccine industry.'' ``Having access to Crucell's novel cell-based technology will enable Aventis Pasteur to maintain its leadership position in next generation vaccine manufacturing,'' commented Jeffrey Almond, Senior Vice President, External Research and Development at Aventis Pasteur. ``We look forward to bringing Crucell's platform to commercialization.'' It is expected that new cell-based manufacturing technology will replace the existing production methods to provide more flexible manufacturing and, potentially, to yield more competitive products.